WK2
WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C76H105N19O10
- Masse moléculaire:1444.77
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
WK2 (2 mg/kg; topical administration; via 10 μL saline drops; 6-36 h post-infection) exhibits antibacterial activity in a mouse skin wound model infected with MRSA, reduces bacterial load, and promotes complete wound healing as well as regeneration of normal skin structure[2].
WK2 (15 mg/kg; i.p.; 30 min post-LPS injection) exhibits selective anti-inflammatory activity in a mouse model of LPS-induced systemic inflammation and reduces plasma TNF-α levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (male, 6-8 weeks old, 18-20 g, intratracheal Klebsiella pneumoniae infection (50μL, 1×109 CFU/mL))[2]
-
Dosage:5 mg/kg
-
Administration:i.p.; at 6, 12, 24, 30, and 36 h post-infection
-
Result:Reduced lung Klebsiella pneumoniae counts to 4.1 × 105 CFU/mg, compared to 2.67 × 106 CFU/mg in untreated infected mice.\nAlleviated inflammatory cell infiltration and promoted alveolar expansion, with less inflammation.
-
Animal Model:BALB/c mice (male, 6-8 weeks old, 18-20 g, dorsal wound methicillin-resistant Staphylococcus aureus infection (10 μL, 1 × 107 CFU/mL) )[2]
-
Dosage:2 mg/kg
-
Administration:topical; via 10 μL saline drops; at 6, 12, 24, 30, and 36 h post-infection
-
Result:Exhibited significant antibacterial activity.
Demonstrated significant anti-MRSA activity, effectively preventing wound ulceration, gradually promoting wound healing, and causing the wound area to gradually decrease over time.
Improved the pathological changes in MRSA-infected mice, including wound thickening, inflammatory cell infiltration, and reduction of sebaceous glands and hair follicles.
-
Animal Model:BALB/c mice (male, 6-8 weeks old, 18-20 g, LPS (10 mg/kg,) i.p.)[2]
-
Dosage:15 mg/kg
-
Administration:i.p.; 30 min post-LPS injection
-
Result:Reduced TNF-α levels induced by LPS.
Chemical Information
-
Masse moléculaire 1444.77
-
Formule C76H105N19O10
-
Sequence
Gly-Trp-Trp-Lys-Lys-Trp-Trp-Lys-Lys-Ile-NH2
-
Sequence Shortening
GWWKKWWKKI-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Ouyang X, et al. Fluorinated Modification as a Simple Strategy That Effectively Enhances the Stability and Activity of Antimicrobial Peptides. J Med Chem. 2025;68(19):20081-20102. [Content Brief]
[2]. Ouyang X, et al. High Therapeutic Index α-Helical AMPs and Their Therapeutic Potential on Bacterial Lung and Skin Wound Infections. ACS Infect Dis. 2024;10(9):3138-3157. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WK2 Related Classifications
HY-P11616 Related Classifications
Powered by Bioz